| 1.14 0.02 (1.79%) | 05-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.6 | 1-year : | 1.86 |
| Resists | First : | 1.37 | Second : | 1.6 |
| Pivot price | 1.05 |
|||
| Supports | First : | 1 | Second : | 0.77 |
| MAs | MA(5) : | 1.11 |
MA(20) : | 1.05  |
| MA(100) : | 3.36 |
MA(250) : | 51.4 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 94.2 |
D(3) : | 85.8 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 800 | Low : | 0.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CNSP ] has closed below upper band by 22.4%. Bollinger Bands are 87.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 1.11 - 1.11 | 1.11 - 1.12 |
| Close: | 1.13 - 1.14 | 1.14 - 1.15 |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Tue, 01 Apr 2025
CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Yahoo Finance
Tue, 01 Apr 2025
CNS Pharma's Strategic Shift: New Cancer Drug Focus as Losses Shrink 21% - Stock Titan
Wed, 26 Mar 2025
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance
Wed, 26 Feb 2025
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing - Yahoo Finance
Wed, 26 Feb 2025
Can CNS Pharmaceuticals' $14M War Chest Deliver on Its Promising Brain Cancer Treatment? - Stock Titan
Wed, 19 Feb 2025
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -13 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.94e+006 (%) |
| Held by Institutions | 2.92e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.49e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 943.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -179.1 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 114.46 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 629850 |
| Forward Dividend | 338690 |
| Dividend Yield | 55250000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|